Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Cancer Res. 2016 Feb 2;76(5):1204–1213. doi: 10.1158/0008-5472.CAN-15-2265

Figure 4. Repression of MYC opposes transformation of G0s2 null MEFs.

Figure 4

A, MYC is effectively knocked down with MYC targeted lentiviral shRNA. Top, Real-time PCR assay, bottom, Immunoblot. Bars are the average of biological triplicates and error bars are standard deviation, * = P < 0.05. B, Left are representative plates from foci formation assays comparing the ability of HRAS expression plasmid to transform G0s2 null cells stably transduced with either shMYC or shControl lentivirus (top) or transiently transfected with shMYC or shControl expression plasmids (bottom). Right, is the average of biological triplicate determinations and error bars are standard deviation, * = P < 0.001. The experiments were repeated three times with similar results. C, BRD4 inhibitor JQ1 inhibits MYC expression in G0s2 null cells. G0s2 null cells were treated with 500 nM JQ1 for the indicated times and MYC expression was assessed by real-time PCR assay (left) and Immunoblot (right). Bars are the average of biological triplicates and error bars are standard deviation, * = P <0.05, ** = P < 0.001. D, G0s2 null MEFs were transfected with HRAS and the following day treated with either 500 nM JQ1 or DMSO (vehicle) every 2 days. Left are representative plates. Right is the average of biological triplicate determinations and error bars are standard deviation, ** = P < .001. The experiment was repeated two times with similar results.